Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Issue 1 (16th June 2021)

• Record Type: Journal Article
• Authors: Drobni, Zsofia D; Murphy, Sean P; Alvi, Raza M; Lee, Charlotte; Gong, Jingyi; Mosarla, Ramya C; Rambarat, Paula K; Hartmann, Sarah B; Gilman, Hannah K; Zubiri, Leyre; Raghu, Vineet K; Sullivan, Ryan J; Zafar, Amna; Zlotoff, Daniel A; Sise, Meghan E; Guidon, Amanda C; Reynolds, Kerry L; Dougan, Michael; Neilan, Tomas G
• Is Part Of: Immunotherapy advances. Volume 1:Issue 1(2021)
• Publication Date: 2021-06-16
• Subjects: skeletal myopathy -- immune checkpoint inhibitors -- statin therapy -- immune-related adverse events; Immunotherapy -- Periodicals; 615.37
• DOI: 10.1093/immadv/ltab014
• Languages: English
• ISSNs: 2732-4303

Abstract

Summary: Objectives: Skeletal myopathies are highly morbid, and in rare cases even fatal, immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI). Skeletal myopathies are also a recognized statin-associated side effect. It is unknown whether concurrent use of statins and ICIs increases the risk of skeletal myopathies. Methods: This was a retrospective cohort study of all patients who were treated with an ICI at a single academic institution (Massachusetts General Hospital, Boston, MA, USA). The primary outcome of interest was the development of a skeletal myopathy. The secondary outcome of interest was an elevated creatine kinase level (above the upper limit of normal). Results: Among 2757 patients, 861 (31.2%) were treated with a statin at the time of ICI start. Statin users were older, more likely to be male and had a higher prevalence of cardiovascular and non-cardiovascular co-morbidities. During a median follow-up of 194 days (inter quartile range 65–410), a skeletal myopathy occurred in 33 patients (1.2%) and was more common among statin users (2.7 vs. 0.9%, P < 0.001). Creatine kinase (CK) elevation was present in 16.3% (114/699) and was higher among statin users (20.0 vs. 14.3%, P = 0.067). In a multivariable Cox model, statin therapy was associated with a >2-fold higher risk for skeletal myopathy (HR, 2.19; 95% confidence interval, 1.07–4.50; P = 0.033). Conclusion: In this large cohort of ICI-treated patients, a higher risk was observed for skeletal myopathies and elevation in CK levels in patients undergoing concurrent statin therapy. Prospective observational studies are warranted to further elucidate the potential association between statin use and ICI-associated myopathies. Graphical Abstract: